Anti-cancer drug hopeful Pharmaust has moved to overcome a limitation discovered in its promising cancer drug known as Monepantel during recent phase 1 human trials. Juniper Pharmaceuticals have been appointed to reformulate the company’s Monepantel drug with the goal being to improve its taste and palatability.
Related Data & Insights
-
-
Rank Company # 163rd I Synergy Group $1.14m 164th Zelira Therapeutics $1.02m 165th Singular Health $935.18k 166th PharmAust $841.71k 198 public companies - industrial WA ranked by total revenue
Data & Insights
Mentioned Organisations
Mentioned People
Related Articles
21 Jun 2024
PharmAust taps investors for $10m
31 May 2024
Shares rise following Thurn return
17 May 2024
Board Moves May 17, 2024
17 May 2024
PharmAust receives FDA approval
13 May 2024
Board Moves May 13, 2024
24 Apr 2024